United Therapeutics CEO Martine Rothblatt reports $ 4.45 million common share disposal

United Therapeutics CEO Martine Rothblatt reported the exercise of options and subsequent sale of 9,500 common shares on July 17, 2026. The trust acquired shares at $135.42 each and sold them at weighted-average prices between $528.91 and $542.43. Following these transactions, the trust's holdings decreased to 324,443 shares.

United Therapeutics Chairperson and CEO Martine A. Rothblatt reported option exercise and share sales on July 17, 2026. * A trust acquired 9,500 common shares via option exercise at $135.42. * The same trust sold 9,500 common shares at weighted-average prices ranging from $528.91 to $542.43. * Trust holdings fell to 324,443 common shares following the transactions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001106578-26-000101), on July 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

United Therapeutics Chairperson and CEO Martine A. Rothblatt reported option exercise and share sales on July 17, 2026. * A trust acquired 9,500 common shares via option exercise at $135.42. * The same trust sold 9,500 common shares at weighted-average prices ranging from $528.91 to $542.43. * Trust holdings fell to 324,443 common shares following the transactions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001106578-26-000101), on July 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here